- Previous Close
1,947.00 - Open
1,965.00 - Bid 1,843.00 x --
- Ask 1,844.00 x --
- Day's Range
1,818.00 - 1,996.00 - 52 Week Range
1,489.00 - 3,235.00 - Volume
12,478,345 - Avg. Volume
13,706,051 - Market Cap (intraday)
206.959B - Beta (5Y Monthly) -1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 2021
- 1y Target Est
--
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.
www.humasis.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 205470.KQ
View MorePerformance Overview: 205470.KQ
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 205470.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 205470.KQ
View MoreValuation Measures
Market Cap
220.31B
Enterprise Value
39.22B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
24.33
Price/Book (mrq)
0.84
Enterprise Value/Revenue
3.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-243.25%
Return on Assets (ttm)
-5.55%
Return on Equity (ttm)
-8.11%
Revenue (ttm)
9.91B
Net Income Avi to Common (ttm)
-24.09B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
196.26B
Total Debt/Equity (mrq)
5.43%
Levered Free Cash Flow (ttm)
-44.97B